DaVita CathAway Program Leads to Lower Catheter Rates in Hemodialysis Patients
July 13 2011 - 8:00AM
Business Wire
DaVita Inc. (NYSE: DVA), a leading provider of kidney care
services for those diagnosed with end stage renal disease (ESRD)
and chronic kidney disease (CKD), today announced that the company
has made landmark progress in reducing “Day 90+” patient central
venous catheter (CVC) rates, further cementing its position as the
industry leader among large dialysis organizations in catheter
reductions through the placement of permanent accesses.
“The success of our catheter-reduction program is a huge
accomplishment for our teammates and physician partners,” explains
Dr. Allen R. Nissenson, DaVita’s chief medical officer. “Decreasing
patients’ chances of infection, thrombosis, hospitalization and
death are the driving forces behind this outstanding continuous
quality improvement program.”
In 2008, DaVita® established CathAway™, the company’s seven-step
program for reducing the number of hemodialysis patients with
catheters. Since the inception of the program, DaVita has witnessed
a 30 percent reduction in the number of “Day 90+” patients
(i.e., those patients who have been dialyzing at DaVita for 90 days
or more) using a catheter for dialysis access and the company
is now at an all-time low catheter rate. This has been
DaVita’s most significant clinical initiative in the past two
years.
Through DaVita’s CathAway program, a multidisciplinary team
including nephrologists, surgeons and clinical teammates helps
patients transition from catheters to fistulas as the means of
dialysis access. Kidney and hemodialysis experts consider the
fistula – a surgically connected passageway between an artery and a
vein that can be used as an access point for dialysis treatments –
the “gold standard” access choice, and research studies have
demonstrated patients with fistulas have the fewest complications,
such as infections and clotting, compared to all other hemodialysis
access choices.
By optimizing the access through which our patients receive
dialysis, DaVita physicians and teammates have helped patients stay
out of the hospital, take fewer medications, increase their quality
of life and even prolong their lives.
DaVita and Cathaway are trademarks or registered trademark of
DaVita Inc. All other trademarks are the property of their
respective owners.
About DaVita
DaVita Inc., a Fortune 500® company, is a leading provider of
kidney care in the United States, delivering dialysis services and
education to patients with chronic kidney failure and end stage
renal disease. As of March 31, 2011, DaVita operated or provided
administrative services at 1,642 dialysis facilities, serving
approximately 128,000 patients. DaVita develops, participates in
and donates to numerous programs dedicated to transforming
communities and creating positive, sustainable change for children,
families and our environment. The company’s leadership development
initiatives and corporate social responsibility efforts have been
recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu,
among others. For more information, please visit
www.davita.com.
DaVita (NYSE:DVA)
Historical Stock Chart
From May 2024 to Jun 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2023 to Jun 2024